Preparation and use of compounds with anti-fibrosis activity in radix isatidis
By extracting and purifying sulfonyl lignan compounds from Isatis indigotica root, the problem of unclear anti-fibrotic components in Isatis indigotica root was solved, and a significant anti-liver fibrosis effect was achieved, providing a new direction for drug development.
CN122404259APending Publication Date: 2026-07-17INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
- Filing Date
- 2025-01-17
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
There are no clear reports in the current technology regarding the anti-fibrotic activity of compounds in Isatis indigotica, especially the effective components for liver fibrosis.
Method used
Sulfonic acid-containing lignan compounds and other types of compounds were extracted and isolated from Isatis indigotica root, purified by multi-column chromatography and HPLC, and combined with pharmaceutically acceptable salts to prepare pharmaceutical compositions for the prevention or treatment of liver fibrosis.
Benefits of technology
The compound exhibits significant anti-hepatic stellate cell activity and anti-hepatic fibrosis effects, making it a lead compound for the development of anti-fibrotic drugs.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122404259A_ABST
Abstract
本发明属于医药技术领域，公开了板蓝根中部分化合物及其用途。具体公开了板蓝根中分离得到的新化合物和已知化合物的抗纤维化活性。细胞水平实验证明：化合物具有一定的抗肝纤维化作用，有望成为与肝纤维化相关的疾病的治疗药物。
Need to check novelty before this filing date? Find Prior Art